Aldeyra Therapeutics Inc. (ALDX)
NASDAQ: ALDX
· Real-Time Price · USD
5.26
-0.04 (-0.75%)
At close: Aug 15, 2025, 10:05 AM
-0.75% (1D)
| Bid | 5.25 |
| Market Cap | 315.05M |
| Revenue (ttm) | 244.53K |
| Net Income (ttm) | -57.7M |
| EPS (ttm) | -0.85 |
| PE Ratio (ttm) | -6.19 |
| Forward PE | 40.38 |
| Analyst | Buy |
| Ask | 5.27 |
| Volume | 61,428 |
| Avg. Volume (20D) | 1,030,169 |
| Open | 5.31 |
| Previous Close | 5.30 |
| Day's Range | 5.25 - 5.34 |
| 52-Week Range | 1.14 - 7.20 |
| Beta | 0.75 |
About ALDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Aldeyra Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-73.36%
Aldeyra Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
9 months ago
+11.64%
Aldeyra Therapeutics shares are trading higher after the FDA accepted its resubmitted new drug application for Reproxalap for the treatment of dry eye disease, prompting the company to announce an expansion of its option agreement with AbbVie.
1 month ago · seekingalpha.com
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber DataAldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for Decem...
